PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2006 June; 7(2): E72–E78.
Published online 2006 April 28. doi:  10.1208/pt070241
PMCID: PMC2750292

Fast-disintegrating sublingual tablets: Effect of epinephrine load on tablet characteristics

Abstract

The aim of this study was to evaluate the effect of increasing epinephrine load on the characteristics of fast-disintegrating sublingual tablets for the potential emergency treatment of anaphylaxis. Four tablet formulations, A, B, C, and D, containing 0%, 6%, 12%, and 24% of epinephrine bitartrate, respectively, and microcrystalline cellulose:low-substituted hydroxypropyl cellulose (9[ratio]1), were prepared by direct compression, at a range of compression forces. Tablet weight variation, content uniformity, hardness, disintegration time, wetting time, and friability were measured for each formulation at each compression force. All 4 tablet formulations at each compression force were within the United States Pharmacopeia (USP) limits for weight variation and content uniformity. A linear increase in compression force resulted in an exponential increase in hardness for all formulations, a linear increase in disintegration and wetting times of A, and an exponential increase in disintegration and wetting times of B, C, and D. At a mean±SD hardness of ≥2.3±0.2 kg, all tablet formulations passed the USP friability test. At a mean±SD hardness of ≤3.1±0.2 kg, all tablet formulations resulted in disintegration and wetting times of <10 seconds and <30 seconds, respectively. Tablets with drug loads from 0% to 24% epinephrine can be formulated with hardness, disintegration times, and wetting times suitable for sublingual administration.

Keywords: sublingual, transmucosal drug delivery, fastdisintegrating tablets, epinephrine, anaphylaxis

Full Text

The Full Text of this article is available as a PDF (249K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Birudaraj R, Berner B, Shen S, Li X. Buccal permeation of buspirone: mechanistic studies on transport pathways. J Pharm Sci. 2005;94:70–78. doi: 10.1002/jps.20208. [PubMed] [Cross Ref]
2. Ishikawa T, Koizumi N, Mukai B, et al. Pharmacokinetics of acetaminophen from rapidly disintegrating compressed tablet prepared using microcrystalline cellulose (PH-M-06) and spherical sugar granules. Chem Pharm Bull (Tokyo) 2001;49:230–232. doi: 10.1248/cpb.49.230. [PubMed] [Cross Ref]
3. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol. Obstet Gynecol. 1997;89:340–345. doi: 10.1016/S0029-7844(96)00513-3. [PubMed] [Cross Ref]
4. Joint Task Force on Practice Parameters; American Academy of Allergy Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115:483–S523. doi: 10.1016/j.jaci.2005.01.010. [PubMed] [Cross Ref]
5. Lieberman P. Use of epinephrine in the treatment of anaphylaxis. Curr Opin Allergy Clin Immunol. 2003;3:313–318. doi: 10.1097/00130832-200308000-00013. [PubMed] [Cross Ref]
6. Simons FER. First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol. 2006;113:837–844. [PubMed]
7. Connors KA, Amidon GL, Stella VJ. Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists. New York, NY: Wiley-Interscience Publications; 1986.
8. Simons KJ, Gu X, Simons FER. Sublingual epinephrine administration in humans: a preliminary study. J Allergy Clin Immunol. 2006;113:260–260. doi: 10.1016/j.jaci.2004.01.405. [Cross Ref]
9. Rawas-Qalaji MM, Simons FE, Simons KJ. Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis. J Allergy Clin Immunol. 2006;117:398–403. doi: 10.1016/j.jaci.2005.12.1310. [PubMed] [Cross Ref]
10. Allen LV. Rapid-dissolve technology: an interview with Loyd V. Allen. Int J Pharm Technol. 2003;7:449–450.
11. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-making and clinical studies. Crit Rev Ther Drug Carrier Syst. 2006;21:433–476. doi: 10.1615/CritRevTherDrugCarrierSyst.v21.i6.10. [PubMed] [Cross Ref]
12. Watanabe Y, Koizumi K, Zama Y, Kiriyama M, Matsumoto Y, Matsumoto M. New compressed tablet rapidly disintegrating in saliva in the mouth using crystalline cellulose and a disintegrant. Biol Pharm Bull. 1995;18:1308–1310. [PubMed]
13. Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity. Chem Pharm Bull (Tokyo) 1996;44:2121–2127. [PubMed]
14. Bi YX, Sunada H, Yonezawa Y, Danjo K. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Drug Dev Ind Pharm. 1999;25:571–581. doi: 10.1081/DDC-100102211. [PubMed] [Cross Ref]
15. Ishikawa T, Mukai B, Shiraishi S, et al. Preparation of rapidly disintegrating tablet using new types of microcrystalline cellulose (PH-M series) and low substituted-hydroxypropylcellulose or spherical sugar granules by direct compression method. Chem Pharm Bull (Tokyo) 2001;49:134–139. doi: 10.1248/cpb.49.134. [PubMed] [Cross Ref]
16. Rawas-Qalaji MM, Simons FE, Simons KJ. Evaluation of the effect of changing tablet dimensions on the characteristics of fast-disintegrating sublingual epinephrine tablets for the first-aid treatment of anaphylaxis away from health care facilities. AAPS J. 2004;6:Abstract W4179.
17. USP/NF . Physical Tests: Uniformity of Dosage Units (905) 26/21 ed. Rockville MD: United States Pharmacopeial Convention Inc; 2003.
18. USP/NF . Physical Tests: Tablet Friability (1216) 26/21 ed. Rockville, MD: United States Pharmacopeial Convention Inc; 2003.
19. Marshall K. Compression and consolidation of powdered solids. In: Lachman L, Lieberman HA, Kanig J, editors. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia, PA: Lea & Febiger; 1986. pp. 66–99.
20. Sugimoto M, Matsubara K, Koida Y, Kobayashi M. The preparation of rapidly disintegrating tablets in the mouth. Pharm Dev Technol. 2001;6:487–493. doi: 10.1081/PDT-120000287. [PubMed] [Cross Ref]
21. Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur J Pharm Sci. 2002;15:295–305. doi: 10.1016/S0928-0987(02)00011-8. [PubMed] [Cross Ref]
22. USP/NF . Physical Tests: Disintegration (701) 22/17 ed. Rockville, MD: United States Pharmacopeial Convention Inc; 1990.
23. USP/NF . Official Monographs: Nitroglycerin Tablets. 22/17 ed. Rockville, MD: United States Pharmacopeial Convention Inc; 1990.
24. Diem K, Lentner C. Scientific Tables. Basle, Switzerland: CibaGeigy Limited; 1971.
25. Abdelbary G, Eouani C, Prinderre P, Joachim J, Reynier J, Piccerelle P. Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration. Int J Pharm. 2005;292:29–41. doi: 10.1016/j.ijpharm.2004.08.019. [PubMed] [Cross Ref]
26. el-Arini SK, Clas SD. Evaluation of disintegration testing of different fast dissolving tablets using the texture analyzer. Pharm Dev Technol. 2002;7:361–371. doi: 10.1081/PDT-120005732. [PubMed] [Cross Ref]
27. Dor PJ, Fix JA. In vitro determination of disintegration time of quick-dissolve tablets using a new method. Pharm Dev Technol. 2000;5:575–577. doi: 10.1081/PDT-100102041. [PubMed] [Cross Ref]
28. Hedenus P, Stromme Mattsson M, Niklasson GA, Camber O, Ek R. Characterisation of instantaneous water absorption properties of pharmaceutical excipients. Int J Pharm. 2000;202:141–149. doi: 10.1016/S0378-5173(00)00436-1. [PubMed] [Cross Ref]
29. Aly A, Semreen M, Qato M. Superdisintegrants for solid dispersion to produce rapidly disintegrating tenoxicam tablets via camphor sublimation. Pharmaceutical Technology. 2005; January 2: 68–78.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists